Clinical outcome in atria fibrillation at gender differences: meta- analysis

Background: Atrial fibrillation is the all-cause risk factors of CVD in females compared to males in the risk ratio of IHD and DM.
Purpose: To characterize the safety efficacies of anti-thrombic agent’s use in the controlling adjustments of treatment preventing ischemic stroke, adding 10 randomized trials to a previous meta-analysis.
Data sources: Identified relevant trials in the literature of bibliography reviews, MEDLINE, and Cochrane (CENTRAL strategy from 2011-2016) obtaining the unpublished data existing in the finding of antithrombic therapy.
Study selection: As the published clinical trials tested controlled endpoints of recovery included in the participation of 987 participants with 6-month long-term atria fibrillation dependent on titrated dosing agents.
Data extraction: Selected studies in the inclusion describe the ascertainment of diagnostic monitoring experience the outcome of SCD in the relevance of cardiac events, HF, MI and all-cause mortality differentiating the interventional hypothetic prevention.
Data synthesis: In 27 study trials included 23,040 participants mean follow-up of (6month-1 year). Compared with warfarin dosing (5 trials, 2400 participants) and antiplatelet agent (7 trials, 4776 participants) in the reduction of 69% and 32% respectively. And without adjustment substantially carry relative risk reduction 44% and 13% (11 trials, 11920 participants).
Limitations: The eligibility of method feature and insufficient data on the impact of post-MI is reported incomplete.
Conclusion: The adjusted-dosing in warfarin and antiplatelet agents are 40% and 34% respectively in the risk factors of AF. Substantially, warfarin remains more efficient by approximately 24% then anti-platelet. The absolute increase of major hemorrhage in the association of trial participants judicious the importance of antithrombic medication in the importance of cardiac-neuro risk factors.